Abstract
Autoimmune diseases such as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and psoriasis cause a considerable degree of morbidity worldwide. Although the treatment of these conditions has shown progress over the last decade with the steady trickle of new drug molecules, drug therapy is far from satisfactory due to the reduced efficacy and maximal toxicity in certain patients. Several factors are known to influence the efficacy and toxicity of these drugs such as age, gender, liver and kidney function, and concomitant drug therapy. Another crucial factor influencing drug response of the patient is the genetic constitution of the patient. For example, polymorphisms in the gene MTHFR such as 677T>C can increase methotrexate serum levels and lead to toxicity in a patient with RA. Similarly polymorphisms in the drug transporter ABCB1 are associated with decreased efficacy to methotrexate. Polymorphisms within the TNF promoter region have been shown to modify the clinical efficacy and toxicity of anti-TNF therapy in RA patients. SLE patients with polymorphic TPMT gene may require a reduced dose of azathioprine to circumvent the catastrophe of fatal bone marrow suppression. Polymorphisms in the TYMS gene could lead to reduced efficacy with methotrexate in psoriatic arthritis patients. Although our understanding of autoimmune diseases has improved considerably over the last decade and several studies in pharmacogenomics of autoimmune diseases have been carried out, the only clinical application is TPMT testing for azathioprine. Yet with improved methodology adopted in pharmacogenomics studies coupled with novel technologies, the field of pharmacogenomics does appear to offer significant promise in the coming years towards the dream of personalized medicine in autoimmune diseases.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Acikbas I, Sanli B, Tepeli E, Ergin S, Aktan S, Bagci H (2012) Vitamin D receptor gene polymorphisms and haplotypes (Apa I, Bsm I, Fok I, Taq I) in Turkish psoriasis patients. Med Sci Monit 18:CR661–CR666
Aggarwal P, Naik S, Mishra KP, Aggarwal A, Misra R (2006) Correlation between methotrexate efficacy & toxicity with C677T polymorphism of the methylenetetrahydrofolate gene in rheumatoid arthritis patients on folate supplementation. Indian J Med Res 124:521–526
Bluett J, Barton A (2012) What have genome-wide studies told us about psoriatic arthritis? Curr Rheumatol Rep 14:364–368
Cargill M, Schrodi SJ, Chang M et al (2007) A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet 80:273–290
Chen H, Poon A, Yeung C et al (2011) A genetic risk score combining ten psoriasis risk loci improves disease prediction. PLoS One 6:e19454
Chouchana L, Narjoz C, Beaune P, Loriot MA, Roblin X (2012) Review article: the benefits of pharmacogenetics for improving thiopurine therapy in inflammatory bowel disease. Aliment Pharmacol Ther 35:15–36
Cobos A, Sanchez P, Aguado J, Carrasco JL (2011) Methodological quality in pharmacogenetic studies with binary assessment of treatment response: a review. Pharmacogenet Genomics 21:243–250
Cooper GS, Stroehla BC (2003) The epidemiology of autoimmune diseases. Autoimmun Rev 2:119–125
Coulthard LR, Taylor JC, Eyre S et al (2011) Genetic variants within the MAP kinase signalling network and anti-TNF treatment response in rheumatoid arthritis patients. Ann Rheum Dis 70:98–103
Criswell LA, Lum RF, Turner KN et al (2004) The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept. Arthritis Rheum 50:2750–2756
Cuchacovich M, Ferreira L, Aliste M et al (2004) Tumour necrosis factor-alpha (TNF-alpha) levels and influence of −308 TNF-alpha promoter polymorphism on the responsiveness to infliximab in patients with rheumatoid arthritis. Scand J Rheumatol 33:228–232
Cui J, Saevarsdottir S, Thomson B et al (2010) Rheumatoid arthritis risk allele PTPRC is also associated with response to anti-tumor necrosis factor alpha therapy. Arthritis Rheum 62:1849–1861
Davila L, Ranganathan P (2011) Pharmacogenetics: implications for therapy in rheumatic diseases. Nat Rev Rheumatol 7:537–550
Davis JP, Cain GA, Pitts WJ, Magolda RL, Copeland RA (1996) The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase. Biochemistry 35:1270–1273
de Rotte MC, Luime JJ, Bulatovic M, Hazes JM, Wulffraat NM, de Jonge R (2010) Do snapshot statistics fool us in MTX pharmacogenetic studies in arthritis research? Rheumatology (Oxford) 49:1200–1201
De IS, Stocco G, Martelossi S et al (2011) Genetic predictors of glucocorticoid response in pediatric patients with inflammatory bowel diseases. J Clin Gastroenterol 45:e1–e7
Duerr RH, Taylor KD, Brant SR et al (2006) A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 314:1461–1463
Dziedziejko V, Kurzawski M, Safranow K, Chlubek D, Pawlik A (2011) The effect of ESR1 and ESR2 gene polymorphisms on the outcome of rheumatoid arthritis treatment with leflunomide. Pharmacogenomics 12:41–47
Fisher MC, Cronstein BN (2009) Metaanalysis of methylenetetrahydrofolate reductase (MTHFR) polymorphisms affecting methotrexate toxicity. J Rheumatol 36:539–545
Gladman DD, Antoni C, Mease P, Clegg DO, Nash P (2005) Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 64(Suppl 2):ii14–ii17
Grabar PB, Rozman B, Logar D, Praprotnik S, Dolzan V (2009) Dihydroorotate dehydrogenase polymorphism influences the toxicity of leflunomide treatment in patients with rheumatoid arthritis. Ann Rheum Dis 68:1367–1368
Haider AS, Lowes MA, Suarez-Farinas M et al (2008) Identification of cellular pathways of “type 1,” Th17 T cells, and TNF- and inducible nitric oxide synthase-producing dendritic cells in autoimmune inflammation through pharmacogenomic study of cyclosporine A in psoriasis. J Immunol 180:1913–1920
Halsall JA, Osborne JE, Pringle JH, Hutchinson PE (2005) Vitamin D receptor gene polymorphisms, particularly the novel A-1012G promoter polymorphism, are associated with vitamin D3 responsiveness and non-familial susceptibility in psoriasis. Pharmacogenet Genomics 15:349–355
Haritunians T, Taylor KD, Targan SR et al (2010) Genetic predictors of medically refractory ulcerative colitis. Inflamm Bowel Dis 16:1830–1840
Hebert HL, Ali FR, Bowes J, Griffiths CE, Barton A, Warren RB (2012) Genetic susceptibility to psoriasis and psoriatic arthritis: implications for therapy. Br J Dermatol 166:474–482
Hoebert JM, Mantel-Teeuwisse AK, van Dijk L, Bijlsma JW, Leufkens HG (2012) Do rheumatoid arthritis patients have equal access to treatment with new medicines?: tumour necrosis factor-alpha inhibitors use in four European countries. Health Policy 104:76–83
Hughes LB, Beasley TM, Patel H et al (2006) Racial or ethnic differences in allele frequencies of single-nucleotide polymorphisms in the methylenetetrahydrofolate reductase gene and their influence on response to methotrexate in rheumatoid arthritis. Ann Rheum Dis 65:1213–1218
Ishihara S, Aziz MM, Yuki T, Kazumori H, Kinoshita Y (2009) Inflammatory bowel disease: review from the aspect of genetics. J Gastroenterol 44:1097–1108
Jankovic S, Raznatovic M, Marinkovic J et al (2011) Health-related quality of life in patients with psoriasis. J Cutan Med Surg 15:29–36
Jorgensen AL, Williamson PR (2008) Methodological quality of pharmacogenetic studies: issues of concern. Stat Med 27:6547–6569
Jurgens M, Laubender RP, Hartl F et al (2010) Disease activity, ANCA, and IL23R genotype status determine early response to infliximab in patients with ulcerative colitis. Am J Gastroenterol 105:1811–1819
Kelly PJ, Stallard N, Whittaker JC (2005) Statistical design and analysis of pharmacogenetic trials. Stat Med 24:1495–1508
Langley RG, Krueger GG, Griffiths CE (2005) Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis 64(Suppl 2):ii18–ii23; discussion ii24–ii5
Lee YH, Song GG (2010) Associations between the C677T and A1298C polymorphisms of MTHFR and the efficacy and toxicity of methotrexate in rheumatoid arthritis: a meta-analysis. Clin Drug Investig 30:101–108
Lee YH, Rho YH, Choi SJ, Ji JD, Song GG (2006) Association of TNF-alpha −308 G/A polymorphism with responsiveness to TNF-alpha-blockers in rheumatoid arthritis: a meta-analysis. Rheumatol Int 27:157–161
Lee YC, Cui J, Costenbader KH, Shadick NA, Weinblatt ME, Karlson EW (2009) Investigation of candidate polymorphisms and disease activity in rheumatoid arthritis patients on methotrexate. Rheumatology (Oxford) 48:613–617
Lee YH, Ji JD, Bae SC, Song GG (2010) Associations between tumor necrosis factor-alpha (TNF-alpha) −308 and −238 G/A polymorphisms and shared epitope status and responsiveness to TNF-alpha blockers in rheumatoid arthritis: a metaanalysis update. J Rheumatol 37:740–746
Lee YH, Bae SC, Choi SJ, Ji JD, Song GG (2012) Associations between TNFAIP3 gene polymorphisms and rheumatoid arthritis: a meta-analysis. Inflamm Res 61:635–641
Leonardi CL, Kimball AB, Papp KA et al (2008) Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 371:1665–1674
Liu Y, Helms C, Liao W et al (2008) A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci. PLoS Genet 4:e1000041
Loftus EV Jr (2004) Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology 126:1504–1517
Louis E, Franchimont D, Piron A et al (1998) Tumour necrosis factor (TNF) gene polymorphism influences TNF-alpha production in lipopolysaccharide (LPS)-stimulated whole blood cell culture in healthy humans. Clin Exp Immunol 113:401–406
Mak RK, Hundhausen C, Nestle FO (2009) Progress in understanding the immunopathogenesis of psoriasis. Actas Dermosifiliogr 100(Suppl 2):2–13
Milic V, Jekic B, Lukovic L et al (2012) Association of dihydrofolate reductase (DHFR) -317AA genotype with poor response to methotrexate in patients with rheumatoid arthritis. Clin Exp Rheumatol 30:178–183
Mittal N, Mittal R, Sharma A, Jose V, Wanchu A, Singh S (2012) Treatment failure with disease-modifying antirheumatic drugs in rheumatoid arthritis patients. Singap Med J 53:532–536
Molodecky NA, Soon IS, Rabi DM et al (2012) Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 142:46–54
Montrone M, Martorelli D, Rosato A, Dolcetti R (2009) Retinoids as critical modulators of immune functions: new therapeutic perspectives for old compounds. Endocr Metab Immune Disord Drug Targets 9:113–131
Nair RP, Duffin KC, Helms C et al (2009) Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat Genet 41:199–204
Ngamjanyaporn P, Thakkinstian A, Verasertniyom O et al (2011) Pharmacogenetics of cyclophosphamide and CYP2C19 polymorphism in Thai systemic lupus erythematosus. Rheumatol Int 31:1215–1218
Niriella MA, De Silva AP, Dayaratne AH et al (2010) Prevalence of inflammatory bowel disease in two districts of Sri Lanka: a hospital based survey. BMC Gastroenterol 10:32
Owlia MB, Mostafavi Pour Manshadi SM, Naderi N (2012) Cardiac manifestations of rheumatological conditions: a narrative review. ISRN Rheumatol 2012:463620. doi:10.5402/2012/463620, Epub 2012 Oct 17
Pawlik A, Herczynska M, Kurzawski M, Safranow K, Dziedziejko V, Drozdzik M (2009) The effect of exon (19C > A) dihydroorotate dehydrogenase gene polymorphism on rheumatoid arthritis treatment with leflunomide. Pharmacogenomics 10:303–309
Potter C, Cordell HJ, Barton A et al (2010) Association between anti-tumour necrosis factor treatment response and genetic variants within the TLR and NF{kappa}B signalling pathways. Ann Rheum Dis 69:1315–1320
Press RR, de Fijter JW, Guchelaar HJ (2010) Individualizing calcineurin inhibitor therapy in renal transplantation–current limitations and perspectives. Curr Pharm Des 16:176–186
Ranganathan P, Culverhouse R, Marsh S et al (2008) Methotrexate (MTX) pathway gene polymorphisms and their effects on MTX toxicity in Caucasian and African American patients with rheumatoid arthritis. J Rheumatol 35:572–579
Reichert JM (2012) Marketed therapeutic antibodies compendium. MAbs 4:413–415
Schmeling H, Biber D, Heins S, Horneff G (2005) Influence of methylenetetrahydrofolate reductase polymorphisms on efficacy and toxicity of methotrexate in patients with juvenile idiopathic arthritis. J Rheumatol 32:1832–1836
Smits KM, Schouten JS, Smits LJ, Stelma FF, Nelemans P, Prins MH (2005) A review on the design and reporting of studies on drug-gene interaction. J Clin Epidemiol 58:651–654
Tan RJ, Gibbons LJ, Potter C et al (2010) Investigation of rheumatoid arthritis susceptibility genes identifies association of AFF3 and CD226 variants with response to anti-tumour necrosis factor treatment. Ann Rheum Dis 69:1029–1035
Taniguchi A, Urano W, Tanaka E et al (2007) Validation of the associations between single nucleotide polymorphisms or haplotypes and responses to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a proposal for prospective pharmacogenomic study in clinical practice. Pharmacogenet Genomics 17:383–390
Taraborelli M, Andreoli L, Archetti S, Ferrari M, Cattaneo R, Tincani A (2009a) Methylenetetrahydrofolate reductase polymorphisms in methotrexate treatment of rheumatoid arthritis patients. Review of the literature and personal experience. Reumatismo 61:98–106
Taraborelli M, Andreoli L, Archetti S, Ferrari M, Cattaneo R, Tincani A (2009b) Methylenetetrahydrofolate reductase polymorphisms and methotrexate: no association with response to therapy nor with drug-related adverse events in an Italian population of rheumatic patients. Clin Exp Rheumatol 27:499–502
Vasku V, Bienertova VJ, Pavkova GM, Vasku A (2007) Three retinoid X receptor gene polymorphisms in plaque psoriasis and psoriasis guttata. Dermatology 214:118–124
Wahie S, Daly AK, Cordell HJ et al (2011) Clinical and pharmacogenetic influences on response to hydroxychloroquine in discoid lupus erythematosus: a retrospective cohort study. J Investig Dermatol 131:1981–1986
Warren RB, Smith RL, Campalani E et al (2009) Outcomes of methotrexate therapy for psoriasis and relationship to genetic polymorphisms. Br J Dermatol 160:438–441
Weizman AV, Silverberg MS (2012) Have genomic discoveries in inflammatory bowel disease translated into clinical progress? Curr Gastroenterol Rep 14:139–145
Wessels JA, de Vries-Bouwstra JK, Heijmans BT et al (2006) Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single-nucleotide polymorphisms in genes coding for folate pathway enzymes. Arthritis Rheum 54:1087–1095
Yanagimachi M, Naruto T, Hara T et al (2011) Influence of polymorphisms within the methotrexate pathway genes on the toxicity and efficacy of methotrexate in patients with juvenile idiopathic arthritis. Br J Clin Pharmacol 71:237–243
Young HS, Summers AM, Read IR et al (2006) Interaction between genetic control of vascular endothelial growth factor production and retinoid responsiveness in psoriasis. J Investig Dermatol 126:453–459
Zaba LC, Suarez-Farinas M, Fuentes-Duculan J et al (2009) Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes. J Allergy Clin Immunol 124:1022–1030
Zhong S, Huang M, Yang X et al (2006) Relationship of glutathione S-transferase genotypes with side-effects of pulsed cyclophosphamide therapy in patients with systemic lupus erythematosus. Br J Clin Pharmacol 62:457–472
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer India
About this chapter
Cite this chapter
George, M., Selvarajan, S., Srinivasamurthy, S.K. (2013). Pharmacogenomics of Autoimmune Diseases. In: Barh, D., Dhawan, D., Ganguly, N. (eds) Omics for Personalized Medicine. Springer, New Delhi. https://doi.org/10.1007/978-81-322-1184-6_13
Download citation
DOI: https://doi.org/10.1007/978-81-322-1184-6_13
Published:
Publisher Name: Springer, New Delhi
Print ISBN: 978-81-322-1183-9
Online ISBN: 978-81-322-1184-6
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)